MOTS-c vs Tesamorelin: Not a Fat-Loss Contest

MOTS-c vs tesamorelin is not a ‘which burns more fat’ contest. Tesamorelin has large human trials showing a change in visceral fat—the fat packed around the organs—in adults with HIV-related lipodystrophy, a condition in which fat is distributed abnormally. MOTS-c has interesting mouse research, but no completed trial has published treatment results for native MOTS-c—the unmodified peptide—in people. They also act through different systems.

That makes tesamorelin the better-studied drug, but only for a narrow question. It does not make tesamorelin a general weight-loss treatment, and it does not show that either peptide is better for someone outside the population studied.

MOTS-c vs tesamorelin at a glance

The cleanest way to read the table is this: MOTS-c is early research with an open clinical question. Tesamorelin is a studied medicine with a specific population and endpoint. Neither column supports a broad claim about who loses more body fat.

What the MOTS-c evidence actually shows

MOTS-c is a 16-amino-acid peptide first described in 2015. In the founding Cell Metabolism study, researchers reported that injected MOTS-c prevented diet-related obesity and insulin resistance in mice. That is the source of much of the excitement—and the word mice is the part that matters most.

A 2021 Nature Communications study included ten healthy young men who completed a cycling session. Researchers measured a rise in the MOTS-c their bodies produced; they did not give those men MOTS-c. The treatment and improved running experiments in that paper were again performed in mice. The broader MOTS-c benefits evidence keeps those species separate.

There is no completed peer-reviewed trial reporting fat loss, weight change, exercise performance, or safety after native MOTS-c treatment in people. An ongoing study can eventually answer some of those questions, but a trial plan is not a result.

What tesamorelin has been studied for

Tesamorelin works one step upstream from growth hormone. It copies growth hormone-releasing hormone, or GHRH, which tells the pituitary gland to release the body’s own growth hormone. That can raise IGF-1, a growth signal made mainly by the liver.

Its evidence is much larger and much narrower. A 2010 pooled analysis combined two large late-stage trials in 806 adults with HIV-related lipodystrophy and excess abdominal fat. All were receiving antiretroviral medicines, which treat HIV. At 26 weeks, the trials reported a 15.4% treatment difference in visceral fat measured by CT. Among those who continued tesamorelin through week 52, the average change from their original baseline was 17.5% (Falutz et al., Journal of Clinical Endocrinology & Metabolism).

Those figures are not general fat-loss numbers. The primary measurement was fat around the organs—not total weight or the pinchable fat under the skin. Tesamorelin for belly fat covers that distinction in depth.

The side-effect comparison has the same evidence gap

Tesamorelin has a product label and trial-sized safety data. The current Egrifta WR label reports injection-site reactions in 25% of tesamorelin-treated participants and 14% of those given placebo, an inactive comparison. It also warns about higher IGF-1, fluid retention, glucose intolerance or diabetes, hypersensitivity reactions—meaning allergic reactions—and concerns around active cancer.

MOTS-c does not have an equivalent human dataset. Its side-effect rates cannot be responsibly estimated from mice, from the body’s natural peptide levels, or from a different MOTS-c-like molecule. The honest answer is uncertainty, not a short list of supposedly mild effects. Our MOTS-c side-effects guide explains what is known without turning guesses into rates.

This matters in a comparison. A known 25% injection-site reaction rate can sound worse than an empty MOTS-c column, but an empty column means the measurement has not been done. It does not mean zero risk.

A fresh FDA review sharpened the MOTS-c answer

As of September 9, 2026, the day this article was written, ClinicalTrials.gov listed the 120-person MOTS-MET phase 2, or mid-stage, study as recruiting, with no results posted (record updated April 1, 2026). At its July 23, 2026 Pharmacy Compounding Advisory Committee meeting, FDA staff said they had found no publicly available clinical studies or human exposure data for administered MOTS-c. Staff proposed that the two MOTS-c forms reviewed not be added to the 503A Bulks List, a federal list used in traditional pharmacy compounding (FDA presentation). The committee’s role is advisory, and that review was not final rulemaking.

MOTS-c has never had an FDA-approved product in the United States. Promise’s tesamorelin is dispensed as a compounded medication, which is different from an FDA-approved product: the formulation offered here is not FDA-approved. A licensed provider may still prescribe a compounded formulation; that decision is between you and your doctor.

What a useful “versus” question sounds like

The useful question is not which peptide burns more fat. It is whether either evidence base matches the clinical issue being discussed. For tesamorelin, that means recognizing the HIV-related population, the CT-measured endpoint, and the label’s weight-neutral limitation. For MOTS-c, it means accepting that the outcome and safety data from administered treatment in people have not arrived.

At Promise, a licensed provider reviews every request and prescribes only when the medication is appropriate; not everyone qualifies. The review includes medical history, current medicines, the reason for considering treatment, and what could be measured safely over time. The answer can be MOTS-c, tesamorelin, another approach, or neither.